Molecular Response and Quality of Life in Chronic Myeloid Leukemia Patients Treated with Intermittent TKIs: First Interim Analysis of OPTkIMA Study

Michele Malagola,Alessandra Iurlo, Elisabetta Abruzzese, Massimiliano Bonifacio,Fabio Stagno,Gianni Binotto, Mariella D'Adda,Monia Lunghi, Monica Crugnola,Maria Luisa Ferrari, Francesca Lunghi,Fausto Castagnetti,Gianantonio Rosti, Roberto M. Lemoli,Rosaria Sancetta,Maria Rosaria Coppi, Maria Teresa Corsetti, Giovanna Rege Cambrin,Atelda Romano, Mario Tiribelli,Antonella Russo Rossi,Sabina Russo,Lara Aprile, Monica Bocchia, Lisa Gandolfi, Mirko Farina, Simona Bernardi, Nicola Polverelli, Aldo M. Roccaro, Antonio De Vivo, Michele Baccarani, Domenico Russo

Cancer medicine（2021）

引用 1|浏览0

暂无评分

摘要

Intermittent treatment with TKIs is an option for the great majority (70%–80%) of CML patients who do not achieve a stable deep molecular response and are not eligible for treatment discontinuation. For these patients, the only alternative is to assume TKI continuously, lifelong.

查看译文

关键词

chronic myeloid leukaemia,intermittent,quality of life,tyrosine kinase inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要